Scarica l'app Stockscreener
2.78
3.47%
-0.10
Dopo l'orario di chiusura:
2.78
Precedente Chiudi:
$2.88
Aprire:
$2.9
Volume 24 ore:
83,094
Relative Volume:
0.32
Capitalizzazione di mercato:
$75.26M
Reddito:
-
Utile/perdita netta:
$-49.81M
Rapporto P/E:
-1.2894
EPS:
-2.156
Flusso di cassa netto:
$-42.93M
1 W Prestazione:
+6.92%
1M Prestazione:
+22.47%
6M Prestazione:
-40.09%
1 anno Prestazione:
-81.91%
Intervallo 1D:
$2.74
$2.91
Intervallo di 1 settimana:
$2.53
$3.05
Portata 52W:
$1.60
$15.83
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Confronta ANRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.78 | 70.39M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-23 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-09-03 | Iniziato | Wedbush | Outperform |
| 2024-02-27 | Iniziato | Jefferies | Buy |
| 2024-02-27 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-27 | Iniziato | Stifel | Buy |
| 2024-02-27 | Iniziato | TD Cowen | Outperform |
| 2024-02-27 | Iniziato | William Blair | Outperform |
Mostra tutto
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
What analysts say about Alto Neuroscience Inc. stockBreakneck growth rates - Jammu Links News
Biotech Bargain Or Bust? Alto Neuroscience Faces Trial Test - Finimize
What makes Alto Neuroscience Inc. stock price move sharplyROI Focused Stock Calls - beatles.ru
Why Alto Neuroscience Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Alto Neuroscience Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Alto Neuroscience reprices employee stock options to $2.35 per share By Investing.com - Investing.com South Africa
Alto Neuroscience reprices employee stock options to $2.35 per share - Investing.com
Alto Neuroscience to advance depression drug after promising study - Investing.com
Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright - Defense World
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients - MarketScreener
Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results - TipRanks
Bank of America Corp DE Buys 22,007 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience : Corporate Presentation - marketscreener.com
Two Sigma Investments LP Has $130,000 Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT - MSN
Jane Street Group LLC Increases Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Wellington Management Group LLP Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Consensus Target Price from Analysts - Defense World
Nuveen Asset Management LLC Reduces Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright maintains buy rating on Alto Neuroscience stock By Investing.com - Investing.com Canada
Alto Neuroscience acquires novel TRD treatment candidate By Investing.com - Investing.com South Africa
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal - Yahoo
Alto Neuroscience, Inc. acquired Novel Dopamine Agonist Combination Product Candidate from Chase Pharmaceuticals Corporation, Inc. - MarketScreener
Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc. - TipRanks
Alto Neuroscience Acquires Assets from Chase Therapeutics - TipRanks
Alto Neuroscience acquires dopamine agonist combination candidate - TipRanks
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Yahoo Finance
BNP Paribas Financial Markets Has $180,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience reports progress in depression drug trials By Investing.com - Investing.com South Africa
Alto Neuroscience, Inc. Presents Data At the 2025 American Society of Clinical Psychopharmacology Annual Meeting - marketscreener.com
Alto Neuroscience reports progress in depression drug trials - Investing.com India
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):